Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities

Skin rash during tumor treatment with immunotherapy (anti-PD1 antibody therapy) is a common side effect. If patients suffer from such a skin reaction, they typically suffer from a rash on the chest, back and extremities. The skin reaction is usually treated with cortisone in cream or tablet form. There is already research in humans on the skin reaction under anti-PD1 antibody therapy. Previous studies in humans have shown that certain inflammatory markers are elevated. It is also know that the study drug can help to reduce these inflammatory markers. However, there is currently not enough data available whether the study drug can actually reduce inflammation in the skin in a rash under anti-PD1 antibody therapy. The investigators are therefore examining in this study whether the study drug is effective and well tolerated in a skin rash under anti-PD1 antibody therapy. The study drug contains the active ingredient ruxolitinib and is applied as a cream. The study drug is approved for other skin diseases (vitiligo and atopic eczema) in the USA and in countries of the European Union (EU). Approval in Switzerland is still pending. Only once the efficacy of the study drug against skin rashes under anti-PD1 antibody therapy has been scientifically investigated and proven can it be approved and used as a therapy in Switzerland. In this study, the participants are not divided into groups. Each study patient receives the test substance.

NCT Number	NCT06399029
Lead Sponsor	University of Zurich Collaborators: Incyte Corporation
Conditions	Exanthema, Lichenoid Skin Rashes Under Anti-PD1 Tumor Therapy
Enrollment	22 participants
Start Date	2024-10-10
Primary Completion	2026-04-22 (estimated)
Study Completion	2026-05 (estimated)
Updated on ClinicalTrials.gov	2026-04-30